Luxbright AB (publ) (LXB.ST)
SEK 0.77
(-2.54%)
SEK 0.77
(-2.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -13.83 Million SEK | -97.34% |
| 2022 | -7.01 Million SEK | -9.34% |
| 2021 | -6.41 Million SEK | 76.86% |
| 2020 | -27.7 Million SEK | -548.2% |
| 2019 | -4.27 Million SEK | 24.21% |
| 2018 | -5.63 Million SEK | -183.36% |
| 2017 | 6.76 Million SEK | 198.06% |
| 2016 | -6.89 Million SEK | -504.66% |
| 2015 | -1.14 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.13 Million SEK | 70.08% |
| 2024 Q2 | -4.13 Million SEK | 0.0% |
| 2023 Q3 | -13.83 Million SEK | 45.13% |
| 2023 Q4 | -13.83 Million SEK | 0.0% |
| 2023 Q1 | -25.21 Million SEK | -259.64% |
| 2023 Q2 | -25.21 Million SEK | 0.0% |
| 2023 FY | -13.83 Million SEK | -97.34% |
| 2022 Q4 | -7.01 Million SEK | 0.0% |
| 2022 Q3 | -7.01 Million SEK | 67.4% |
| 2022 Q2 | -21.5 Million SEK | 0.0% |
| 2022 Q1 | -21.5 Million SEK | -235.37% |
| 2022 FY | -7.01 Million SEK | -9.34% |
| 2021 Q1 | -18.86 Million SEK | 31.92% |
| 2021 Q3 | -6.41 Million SEK | 66.01% |
| 2021 FY | -6.41 Million SEK | 76.86% |
| 2021 Q4 | -6.41 Million SEK | -0.0% |
| 2021 Q2 | -18.86 Million SEK | 0.0% |
| 2020 Q4 | -27.7 Million SEK | -0.0% |
| 2020 Q2 | -8.19 Million SEK | -0.0% |
| 2020 Q1 | -8.19 Million SEK | -91.68% |
| 2020 FY | -27.7 Million SEK | -548.2% |
| 2020 Q3 | -27.7 Million SEK | -238.15% |
| 2019 Q1 | 8.1 Million SEK | 0.0% |
| 2019 FY | -4.27 Million SEK | 24.21% |
| 2019 Q4 | -4.27 Million SEK | -0.01% |
| 2019 Q2 | -12.42 Million SEK | -253.23% |
| 2019 Q3 | -4.27 Million SEK | 65.6% |
| 2018 FY | -5.63 Million SEK | -183.36% |
| 2017 FY | 6.76 Million SEK | 198.06% |
| 2016 FY | -6.89 Million SEK | -504.66% |
| 2015 FY | -1.14 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 60.643% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 101.128% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 101.128% |
| Arcoma AB | -1.12 Million SEK | -1126.371% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 112.589% |
| BICO Group AB (publ) | 927.9 Million SEK | 101.491% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 110.74% |
| CellaVision AB (publ) | -56.94 Million SEK | 75.706% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 7.014% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -63.609% |
| C-Rad AB (publ) | -127.6 Million SEK | 89.159% |
| Duearity AB (publ) | 10.23 Million SEK | 235.211% |
| Dignitana AB (publ) | 13.07 Million SEK | 205.785% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 73.751% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.256% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 60.536% |
| Iconovo AB (publ) | -10.75 Million SEK | -28.62% |
| Integrum AB (publ) | -10.47 Million SEK | -32.042% |
| Mentice AB (publ) | -49.56 Million SEK | 72.09% |
| OssDsign AB (publ) | -162.78 Million SEK | 91.502% |
| Paxman AB (publ) | -11.41 Million SEK | -21.229% |
| Promimic AB (publ) | -50.32 Million SEK | 72.511% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 172.54% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 49.372% |
| ScandiDos AB (publ) | -1.53 Million SEK | -803.558% |
| Sectra AB (publ) | -772.85 Million SEK | 98.21% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 93.903% |
| Senzime AB (publ) | -139.54 Million SEK | 90.086% |
| SpectraCure AB (publ) | -50.23 Million SEK | 72.462% |
| Stille AB | -178.5 Million SEK | 92.25% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 101.127% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 93.555% |